ResMed (RMD) Stock Forecast, Price Target & Predictions
RMD Stock Forecast
ResMed stock forecast is as follows: an average price target of $209.33 (represents a -15.91% downside from RMD’s last price of $248.93) and a rating consensus of 'Hold', based on 21 wall street analysts offering a 1-year stock forecast.
RMD Price Target
The average price target for ResMed (RMD) is $209.33 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $250.00 to $175.00. This represents a potential -15.91% downside from RMD's last price of $248.93.
RMD Analyst Ratings
According to 21 Wall Street analysts, ResMed's rating consensus is 'Hold'. The analyst rating breakdown for RMD stock is 0 'Strong Buy' (0.00%), 9 'Buy' (42.86%), 11 'Hold' (52.38%), 1 'Sell' (4.76%), and 0 'Strong Sell' (0.00%).
ResMed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 10, 2024 | Craig Wong-Pan | RBC Capital | $187.00 | $194.27 | -3.74% | -24.88% |
| Apr 01, 2024 | Mike Matson | Stifel Nicolaus | $224.00 | $198.03 | 13.11% | -10.01% |
| Oct 27, 2023 | Suraj Kalia | Oppenheimer | $175.00 | $134.65 | 29.97% | -29.70% |
| Sep 06, 2023 | Mike Matson | Needham | $180.00 | $153.89 | 16.97% | -27.69% |
| Jun 20, 2022 | Craig Wong-Pan | RBC Capital | $244.00 | $197.57 | 23.50% | -1.98% |
| Apr 29, 2022 | - | RBC Capital | $233.00 | $200.81 | 16.03% | -6.40% |
| Oct 14, 2021 | Suraj Kalia | Oppenheimer | $312.00 | $253.77 | 22.95% | 25.34% |
| Aug 04, 2021 | Sean Laaman | Morgan Stanley | $250.00 | $271.87 | -8.04% | 0.43% |
| Jul 28, 2021 | Anthony Petrone | Jefferies | $240.00 | $264.75 | -9.35% | -3.59% |
The latest ResMed stock forecast, released on Apr 10, 2024 by Craig Wong-Pan from RBC Capital, set a price target of $187.00, which represents a -3.74% decrease from the stock price at the time of the forecast ($194.27), and a -24.88% decrease from RMD last price ($248.93).
ResMed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $195.33 |
| Last Closing Price | $248.93 | $248.93 | $248.93 |
| Upside/Downside | -100.00% | -100.00% | -21.53% |
In the current month, the average price target of ResMed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ResMed's last price of $248.93. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Sep 04, 2024 | Needham | Buy | Hold | Downgrade |
| Aug 27, 2024 | William Blair | Outperform | Outperform | Hold |
| Aug 02, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Jul 23, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jun 25, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jun 25, 2024 | Oppenheimer | Outperform | Perform | Downgrade |
| Apr 01, 2024 | Needham | Buy | Buy | Hold |
| Mar 27, 2024 | UBS | Sector Perform | Sector Perform | Hold |
| Jan 25, 2024 | Needham | Buy | Buy | Hold |
ResMed's last stock rating was published by RBC Capital on Sep 04, 2024. The company gave RMD a "Sector Perform" rating, the same as its previous rate.
ResMed Financial Forecast
ResMed Revenue Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.16B | - | $1.12B | $1.12B | $1.03B | $950.29M | - | $864.50M | $894.87M | $904.01M | $876.10M | $768.77M | $800.01M | $751.94M | $770.34M | $769.46M |
| Avg Forecast | $1.46B | $1.42B | $1.40B | $1.30B | $1.40B | $1.36B | $1.33B | $1.26B | $1.32B | $1.29B | $1.26B | $1.19B | $1.22B | $1.17B | $1.15B | $1.10B | $1.14B | $1.05B | $996.10M | $949.78M | $910.56M | $904.59M | $921.91M | $856.61M | $799.54M | $797.03M | $782.57M | $710.06M | $752.04M | $724.07M |
| High Forecast | $1.55B | $1.50B | $1.48B | $1.38B | $1.48B | $1.44B | $1.41B | $1.33B | $1.39B | $1.36B | $1.33B | $1.23B | $1.29B | $1.24B | $1.19B | $1.13B | $1.21B | $1.11B | $1.05B | $1.00B | $910.56M | $926.30M | $944.03M | $877.16M | $818.72M | $816.16M | $801.35M | $727.10M | $770.09M | $741.45M |
| Low Forecast | $1.44B | $1.40B | $1.37B | $1.28B | $1.38B | $1.34B | $1.31B | $1.23B | $1.30B | $1.27B | $1.24B | $1.17B | $1.20B | $1.15B | $1.13B | $1.06B | $1.12B | $1.03B | $979.79M | $934.23M | $910.56M | $885.53M | $902.48M | $838.56M | $782.69M | $780.24M | $766.08M | $695.10M | $736.20M | $708.81M |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 4 | 4 | 7 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | - | 0.98% | 1.06% | 1.04% | 1.00% | - | 0.96% | 0.97% | 1.06% | 1.10% | 0.96% | 1.02% | 1.06% | 1.02% | 1.06% |
ResMed's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.17B, with a low forecast of $1.15B, and a high forecast of $1.24B. RMD's average Quarter revenue forecast represents a 0.98% increase compared to the company's last Quarter revenue of $1.16B (Dec 23).
ResMed EBITDA Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 4 | 4 | 7 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $275.09M | - | $333.76M | $347.04M | $342.56M | $319.77M | - | $285.87M | $280.94M | $306.41M | $290.24M | $271.76M | $264.58M | $272.58M | $266.80M | $248.09M |
| Avg Forecast | $489.49M | $475.78M | $468.06M | $436.77M | $469.08M | $455.54M | $445.22M | $420.58M | $441.32M | $431.93M | $420.73M | $398.44M | $408.21M | $367.05M | $385.43M | $369.69M | $382.50M | $333.68M | $333.74M | $299.87M | $301.81M | $303.35M | $296.33M | $272.61M | $267.02M | $265.35M | $235.42M | $209.07M | $205.04M | $191.38M |
| High Forecast | $517.71M | $503.22M | $495.05M | $461.95M | $496.13M | $481.81M | $470.89M | $444.83M | $466.77M | $456.84M | $444.99M | $411.83M | $431.75M | $440.46M | $398.72M | $378.12M | $404.56M | $400.42M | $352.99M | $359.85M | $301.81M | $364.02M | $355.60M | $327.13M | $320.42M | $318.41M | $282.50M | $250.88M | $246.05M | $229.66M |
| Low Forecast | $481.47M | $467.99M | $460.40M | $429.61M | $461.40M | $448.08M | $437.93M | $413.70M | $434.10M | $424.86M | $413.84M | $391.74M | $401.53M | $293.64M | $378.79M | $354.50M | $376.24M | $266.95M | $328.28M | $239.90M | $301.81M | $242.68M | $237.06M | $218.09M | $213.61M | $212.28M | $188.33M | $167.26M | $164.03M | $153.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.71% | - | 0.87% | 1.04% | 1.03% | 1.07% | - | 0.94% | 0.95% | 1.12% | 1.09% | 1.02% | 1.12% | 1.30% | 1.30% | 1.30% |
3 analysts predict RMD's average Quarter EBITDA for Mar 24 to be $367.05M, with a high of $440.46M and a low of $293.64M. This is 33.43% upper than ResMed's previous annual EBITDA (Dec 23) of $275.09M.
ResMed Net Income Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 4 | 4 | 7 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $208.80M | - | $229.66M | $232.50M | $224.91M | $210.48M | - | $179.01M | $201.75M | $203.61M | $195.10M | $-78.48M | $179.51M | $178.37M | $177.84M | $163.14M |
| Avg Forecast | $409.61M | $394.34M | $386.51M | $351.70M | $383.83M | $371.98M | $363.13M | $333.29M | $355.34M | $346.57M | $334.26M | $303.86M | $307.27M | $231.86M | $262.04M | $238.87M | $247.73M | $210.78M | $238.18M | $199.27M | $212.60M | $191.62M | $208.39M | $181.16M | $179.49M | $-76.63M | $159.73M | $136.81M | $136.67M | $125.85M |
| High Forecast | $440.32M | $423.90M | $415.48M | $378.07M | $412.60M | $399.87M | $390.36M | $358.28M | $381.98M | $372.55M | $359.32M | $312.88M | $330.31M | $278.23M | $275.07M | $247.72M | $266.30M | $252.94M | $256.03M | $239.13M | $212.60M | $229.94M | $250.07M | $217.39M | $215.39M | $-61.30M | $191.67M | $164.17M | $164.00M | $151.02M |
| Low Forecast | $400.89M | $385.95M | $378.28M | $344.22M | $375.66M | $364.06M | $355.41M | $326.20M | $347.78M | $339.20M | $327.15M | $293.33M | $300.73M | $185.49M | $253.35M | $228.55M | $242.46M | $168.62M | $233.11M | $159.42M | $212.60M | $153.29M | $166.71M | $144.92M | $143.59M | $-91.95M | $127.78M | $109.45M | $109.34M | $100.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | - | 0.93% | 1.10% | 0.94% | 1.06% | - | 0.93% | 0.97% | 1.12% | 1.09% | 1.02% | 1.12% | 1.30% | 1.30% | 1.30% |
ResMed's average Quarter net income forecast for Mar 24 is $231.86M, with a range of $185.49M to $278.23M. RMD's average Quarter net income forecast represents a 11.04% increase compared to the company's last Quarter net income of $208.80M (Dec 23).
ResMed SG&A Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 4 | 4 | 7 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $222.16M | - | $240.69M | $228.46M | $211.67M | $193.93M | - | $182.40M | $185.36M | $176.72M | $181.48M | $160.45M | $169.47M | $158.99M | $165.38M | $172.44M |
| Avg Forecast | $306.18M | $297.61M | $292.78M | $273.20M | $293.41M | $284.95M | $278.49M | $263.08M | $276.05M | $270.18M | $263.17M | $249.23M | $255.34M | $236.25M | $241.09M | $231.25M | $239.26M | $214.77M | $208.76M | $172.95M | $200.25M | $195.25M | $191.46M | $157.23M | $166.96M | $156.66M | $150.79M | $121.94M | $127.10M | $133.03M |
| High Forecast | $323.84M | $314.77M | $309.66M | $288.96M | $310.33M | $301.38M | $294.55M | $278.25M | $291.97M | $285.76M | $278.35M | $257.61M | $270.07M | $283.50M | $249.41M | $236.52M | $253.06M | $257.72M | $220.80M | $207.54M | $200.25M | $234.30M | $229.75M | $188.67M | $200.36M | $187.99M | $180.95M | $146.33M | $152.52M | $159.63M |
| Low Forecast | $301.17M | $292.73M | $287.99M | $268.73M | $288.61M | $280.28M | $273.93M | $258.77M | $271.53M | $265.76M | $258.87M | $245.04M | $251.16M | $189.00M | $236.94M | $221.74M | $235.35M | $171.82M | $205.34M | $138.36M | $200.25M | $156.20M | $153.17M | $125.78M | $133.57M | $125.32M | $120.63M | $97.55M | $101.68M | $106.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | - | 1.01% | 1.06% | 1.01% | 1.12% | - | 0.93% | 0.97% | 1.12% | 1.09% | 1.02% | 1.12% | 1.30% | 1.30% | 1.30% |
ResMed's average Quarter SG&A projection for Mar 24 is $236.25M, based on 3 Wall Street analysts, with a range of $189.00M to $283.50M. The forecast indicates a 6.34% rise compared to RMD last annual SG&A of $222.16M (Dec 23).
ResMed EPS Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 4 | 4 | 7 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.56 | $1.58 | $1.53 | $1.44 | - | $1.22 | $1.38 | $1.40 | $1.34 | $-0.54 | $1.24 | $1.23 | $1.23 | $1.13 |
| Avg Forecast | $2.78 | $2.67 | $2.62 | $2.38 | $2.60 | $2.52 | $2.46 | $2.26 | $2.41 | $2.35 | $2.27 | $2.06 | $2.08 | $1.93 | $1.78 | $1.62 | $1.68 | $1.61 | $1.61 | $1.53 | $1.44 | $1.46 | $1.50 | $1.37 | $1.29 | $1.29 | $1.27 | $1.02 | $1.10 | $1.03 |
| High Forecast | $2.98 | $2.87 | $2.82 | $2.56 | $2.80 | $2.71 | $2.65 | $2.43 | $2.59 | $2.53 | $2.44 | $2.12 | $2.24 | $2.07 | $1.86 | $1.68 | $1.81 | $1.73 | $1.74 | $1.65 | $1.44 | $1.50 | $1.54 | $1.41 | $1.33 | $1.33 | $1.31 | $1.05 | $1.13 | $1.07 |
| Low Forecast | $2.72 | $2.62 | $2.56 | $2.33 | $2.55 | $2.47 | $2.41 | $2.21 | $2.36 | $2.30 | $2.22 | $1.99 | $2.04 | $1.89 | $1.72 | $1.55 | $1.64 | $1.57 | $1.58 | $1.50 | $1.44 | $1.42 | $1.45 | $1.33 | $1.26 | $1.25 | $1.24 | $0.99 | $1.07 | $1.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 0.98% | 0.95% | 0.94% | - | 0.84% | 0.92% | 1.02% | 1.04% | -0.42% | 0.97% | 1.21% | 1.12% | 1.09% |
According to 12 Wall Street analysts, ResMed's projected average Quarter EPS for Sep 23 is $1.62, with a low estimate of $1.55 and a high estimate of $1.68. This represents a 3.79% increase compared to RMD previous annual EPS of $1.56 (Jun 23).
ResMed Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $110.53 | $298.00 | 169.61% | Buy |
| STAA | STAAR Surgical Company | $32.38 | $54.58 | 68.56% | Buy |
| BAX | Baxter | $39.72 | $64.62 | 62.69% | Hold |
| TFX | Teleflex | $246.05 | $304.09 | 23.59% | Buy |
| BDX | Becton, Dickinson and Company | $234.18 | $280.55 | 19.80% | Buy |
| WST | West Pharmaceutical Services | $300.67 | $345.33 | 14.85% | Buy |
| HOLX | Hologic | $81.15 | $78.92 | -2.75% | Buy |
| MMSI | Merit Medical Systems | $96.16 | $93.38 | -2.89% | Buy |
| ALC | Alcon | $98.50 | $93.34 | -5.24% | Buy |
| RMD | ResMed | $248.93 | $209.33 | -15.91% | Hold |
| ICUI | ICU Medical | $179.00 | $135.00 | -24.58% | Buy |
| EMBC | Embecta | $16.02 | $12.00 | -25.09% | Sell |
RMD Forecast FAQ
Is ResMed a good buy?
No, according to 21 Wall Street analysts, ResMed (RMD) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 42.86% of RMD's total ratings.
What is RMD's price target?
ResMed (RMD) average price target is $209.33 with a range of $175 to $250, implying a -15.91% from its last price of $248.93. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ResMed stock go up soon?
According to Wall Street analysts' prediction for RMD stock, the company can go down by -15.91% (from the last price of $248.93 to the average price target of $209.33), up by 0.43% based on the highest stock price target, and down by -29.70% based on the lowest stock price target.
Can ResMed stock reach $400?
RMD's average twelve months analyst stock price target of $209.33 does not support the claim that ResMed can reach $400 in the near future.
What are ResMed's analysts' financial forecasts?
ResMed's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $5.34B (high $5.65B, low $5.26B), average EBITDA is $1.79B (high $1.89B, low $1.76B), average net income is $1.45B (high $1.56B, low $1.42B), average SG&A $1.12B (high $1.18B, low $1.1B), and average EPS is $9.84 (high $10.58, low $9.63). RMD's analysts financial forecasts for the fiscal year (Jun 2027) are as follows: average revenue is $5.58B (high $5.9B, low $5.49B), average EBITDA is $1.87B (high $1.98B, low $1.84B), average net income is $1.54B (high $1.66B, low $1.51B), average SG&A $1.17B (high $1.24B, low $1.15B), and average EPS is $10.45 (high $11.24, low $10.23).
Did the RMD's actual financial results beat the analysts' financial forecasts?
Based on ResMed's last annual report (Jun 2023), the company's revenue was $4.22B, which missed the average analysts forecast of $5.05B by -16.36%. Apple's EBITDA was $1.34B, missing the average prediction of $1.65B by -18.90%. The company's net income was $897.56M, missing the average estimation of $1.11B by -19.03%. Apple's SG&A was $874M, missing the average forecast of $1.04B by -15.64%. Lastly, the company's EPS was $0, missing the average prediction of $7.88 by -100.00%. In terms of the last quarterly report (Dec 2023), ResMed's revenue was $1.16B, beating the average analysts' forecast of $1.15B by 1.08%. The company's EBITDA was $275.09M, missing the average prediction of $385.43M by -28.63%. ResMed's net income was $208.8M, missing the average estimation of $262.04M by -20.32%. The company's SG&A was $222.16M, missing the average forecast of $241.09M by -7.86%. Lastly, the company's EPS was $0, missing the average prediction of $1.78 by -100.00%